OMP-59R5
59R5-003
Phase 2 small_molecule terminated
Quick answer
OMP-59R5 for Stage IV Small Cell Lung Cancer is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Mereo BioPharma Group plc
- Indication
- Stage IV Small Cell Lung Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated